Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAE1 | Q13564 | 5/20 | 0.41 |
| ▸ | UBA3 | Q8TBC4 | 5/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.40 |
| ▸ | ADK | P55263 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23786511 | 0.92 | ADK (0.47) | NAE1UBA3ADORA1ADORA3ADORA2A | |
| SCHEMBL13374198 | 0.84 | ADORA3 (0.52) | ADORA3 | |
| SCHEMBL25969465 | 0.84 | ADORA3 (0.52) | ADORA3 | |
| SCHEMBL14064199 | 0.84 | ADORA3 (0.52) | ADORA3 | |
| SCHEMBL26298205 | 0.84 | ALDH1A1 (0.43) | ADK | |
| SCHEMBL13889496 | 0.84 | ALDH1A1 (0.43) | ADK | |
| SCHEMBL25505312 | 0.84 | ADORA3 (0.52) | ADORA3 | |
| SCHEMBL12601699 | 0.84 | ALDH1A1 (0.43) | ADK | |
| SCHEMBL25504687 | 0.84 | ADORA3 (0.52) | ADORA3 | |
| SCHEMBL18510840 | 0.82 | ADORA3 (0.38) | ADORA1ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230287034-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN BIOTECH INC (US) | 2023-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230287034-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | STING1, CGAS, IFNAR1 | NAE1 2027/4885UBA3 1880/4885ADORA1 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.